21906 Federal Register / Vol. 76, No. 75 / Tuesday, April 19, 2011 / Notices 

request; object class, appropriation code 

and Central Accounting Number (CAN) 

of the item requested; HHS requesting 

organization name; and location, HHS 

point of contact name and business 

contact phone number within the 

requesting organization; a description of 

the item requested and corresponding 

quantity and cost required. Other 

information collected includes; 

proposal, solicitation, market research, 

and contract award documentation. 

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS

OF THE ACT: 

None. 

[FR Doc. 2011–9467 Filed 4–18–11; 8:45 am] 

BILLING CODE 4150–24–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Intent To Award Affordable 

Care Act Funding to Approved 

Applications Formerly Received in 

Response to the Centers for Disease 

Control and Prevention Funding 

Opportunity IP11–010, ‘‘Enhanced 

Surveillance for New Vaccine 

Preventable Disease’’ 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This notice provides public 

announcement of CDC’s intent to fund 

Approved cooperative agreement 

applications previously received and 

competed in response to CDC Funding 

Opportunity, CDC–RFA–IP11–010, 

‘‘Enhanced Surveillance for New 

Vaccine Preventable Disease.’’ It is the 

intent of CDC to fund the applications 

with Patient Protection Affordable Care 

Act (ACA), Section 4002, 

appropriations. 

CFDA Number 93.533 is the ACAspecific CFDA number for this 

initiative. 

Award Information 

Approximate Current Fiscal Year 

Funding: $2,750,000. 

Approximate Number of Awards: 3–5. 

Approximate Average Award: 

$500,000. 

Fiscal Year Funds: Patient Protection 

and Affordable Health Care Act of 2011. 

Anticipated Award Date: 31 May 

2011. 

Budget Period: 12 months. 

Project Period: 5 years. 

Application Selection Process: CDC 

will apply the same selection 

methodology published in the FOA, 

CDC–RFA–IP11–010. 

The following will be considered in 

making funding decisions: 

• Scientific and technical merit of the 

proposed project as determined by 

scientific peer review. 

• Availability of funds. 

• Relevance of the proposed project 

to program priorities. 

• Funding decision criteria will 

include a priority score, programmatic 

importance/value relative to program 

priorities, past and current surveillance 

performance and capabilities, research 

portfolio, geographic locations, and 

study population consideration 

(ethnicity, etc.) 

• Preference may be given to a 

medical institution catchment area 

having a total population of greater than 

500,000 persons. 

• Applicants must have a letter of 

support with a research laboratory for 

rotavirus analyses or they will not be 

funded. 

CDC will add the following Authority 

to that which is reflected in the 

published Funding Opportunity: 

—Section 4002 of the Patient Protection 

and Affordable Care Act (Public Law 

111–148.) 

DATES: The effective date for this action 

is April 19, 2011 and remains in effect 

until the expiration of the project period 

of the ACA funded applications.. 

FOR FURTHER INFORMATION CONTACT: 

Elmira Benson, Deputy Director, Centers 

for Disease Control and Prevention, 

2920 Brandywine Road, Atlanta, GA 

30341, telephone (770) 488–2802, e-mail 

Elmira.Benson@cdc.gov. 

SUPPLEMENTARY INFORMATION: On March 

23, 2010, the President signed into law 

the Patient Protection and Affordable 

Care Act (ACA). ACA is designed to 

improve and expand the scope of health 

care coverage for Americans. Cost 

savings through disease prevention is an 

important element of this legislation 

and ACA has established a Prevention 

and Public Health Fund (PPHF) for this 

purpose. Specifically, the legislation 

states in Section 4002 that the PPHF is 

to ‘‘provide for expanded and sustained 

national investment in prevention and 

public health programs to improve 

health and help restrain the rate of 

growth in private and public sector 

health care costs. ACA and the 

Prevention and Public Health Fund 

make improving public health a priority 

with investments to improve public 

health. 

The PPHF states that the Secretary 

shall transfer amounts in the Fund to 

accounts within the Department of 

Health and Human Services to increase 

funding, over the fiscal year 2008 level, 

for programs authorized by the Public 

Health Services Act, for prevention, 

wellness and public health activities 

including prevention research and 

health screenings, such as the 

Community Transformation Grant 

Program, the Education and Outreach 

Campaign for Preventative Benefits, and 

Immunization Programs. 

ACA legislation affords an important 

opportunity to advance public health 

across the lifespan and to reduce health 

disparities by supporting an intensive 

community approach to chronic disease 

prevention and control. 

Therefore, the FOA program activities 

CDC proposes to fund with ACA 

appropriations are authorized by the 

amendment to the Public Health 

Services Act which authorized the 

Prevention and Wellness Program. 

Dated: April 8, 2011. 

John Murphy, 

Business Operation Manager, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–9417 Filed 4–18–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day–11–11EF] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Daniel Holcomb, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an e-mail to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

mstockstill on DSKH9S0YB1PROD with NOTICES